Avastin Breast Cancer Approval Debate Pits Clinical Benefit Versus Statistics

The Oncology Drugs Advisory Committee's vote against full approval of Roche's Avastin (bevacizumab) for first-line treatment of metastatic breast cancer hinged to a large degree on its feeling that the drug did not delay disease progression long enough to be clinically meaningful